Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine Pharmacokinetics and Cardiac Toxicity in ICU COVID-19 Patients
2020-001281-11Phase 4Terminated
- Sponsor
- CHU Saint-Etienne
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19), sponsored by CHU Saint-Etienne. Primary endpoint: Hydroxychloroquine blood concentration. Started Mar 2020; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001281-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001281-11.